{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:16:38Z","timestamp":1793459798537,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto de Investigaci\u00f3n Sanitaria y Biom\u00e9dica de Alicante-ISABIAL","award":["UGP-16-156"],"award-info":[{"award-number":["UGP-16-156"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1559-2","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:42:15Z","timestamp":1522802535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort"],"prefix":"10.1186","volume":"20","author":[{"given":"Laura","family":"Ranieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Contero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Luisa","family":"Peral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Calabuig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Zapater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0219-9055","authenticated-orcid":false,"given":"Mariano","family":"Andres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,22]]},"reference":[{"key":"1559_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.rdc.2014.01.001","volume":"40","author":"E Roddy","year":"2014","unstructured":"Roddy E, Choi HK. Epidemiology of gout. Rheum Dis Clin N Am. 2014;40:155\u201375.","journal-title":"Rheum Dis Clin N Am"},{"key":"1559_CR2","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1186\/ar4281","volume":"15","author":"CA Scire","year":"2013","unstructured":"Scire CA, Manara M, Cimmino MA, et al. Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ther. 2013;15:R101.","journal-title":"Arthritis Res Ther"},{"key":"1559_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/2047487313514895","volume":"22","author":"LE Clarson","year":"2015","unstructured":"Clarson LE, Chandrate P, Hider SL, et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22:335\u201343.","journal-title":"Eur J Prev Cardiol"},{"key":"1559_CR4","doi-asserted-by":"publisher","first-page":"e007214","DOI":"10.1136\/bmjopen-2014-007214","volume":"5","author":"R Jackson","year":"2015","unstructured":"Jackson R, Shiozawa A, Buysman EK, Altan A, Korrer S, Choi H. Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis. BMJ Open. 2015;5:e007214.","journal-title":"BMJ Open"},{"key":"1559_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29\u201342.","journal-title":"Ann Rheum Dis"},{"key":"1559_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/ard.2005.049023","volume":"65","author":"E Pascual","year":"2006","unstructured":"Pascual E, Perdiguero M. Gout, diuretics and the kidney. Ann Rheum Dis. 2006;65:981\u20132.","journal-title":"Ann Rheum Dis"},{"key":"1559_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/annrheumdis-2013-203779","volume":"74","author":"P Richette","year":"2015","unstructured":"Richette P, Clerson P, Perissin L, Flipo RM, Bardin T. Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis. 2015;74:142\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1559_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1053\/j.ajkd.2017.01.055","volume":"70","author":"AB Vargas-Santos","year":"2017","unstructured":"Vargas-Santos AB, Neogi T. Management of gout and hyperuricemia in CKD. Am J Kidney Dis. 2017;70(3):422\u201339.","journal-title":"Am J Kidney Dis"},{"key":"1559_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","volume":"15","author":"T Bardin","year":"2017","unstructured":"Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15:123.","journal-title":"BMC Med"},{"key":"1559_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/bcp.12799","volume":"81","author":"DF Wright","year":"2016","unstructured":"Wright DF, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK. Predicting allopurinol response in patients with gout. Br J Clin Pharmacol. 2016;81:277\u201389.","journal-title":"Br J Clin Pharmacol"},{"key":"1559_CR11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1136\/annrheumdis-2016-209467","volume":"76","author":"U Kiltz","year":"2017","unstructured":"Kiltz U, Smolen J, Bardin T. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017;76:632\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1559_CR12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1136\/annrheumdis-2016-210357","volume":"76","author":"M Andr\u00e9s","year":"2017","unstructured":"Andr\u00e9s M, Bernal JA, Quilis N, Sivera F, Carmona L, Vela P, Pascual E. Cardiovascular risk of gout patients seen at rheumatology clinics following a structured assessment. Ann Rheum Dis. 2017;76:1263\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1559_CR13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Int Med. 2009;150:604\u201312.","journal-title":"Ann Int Med"},{"key":"1559_CR14","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1111\/bcp.13307","volume":"83","author":"DRW Kannangara","year":"2017","unstructured":"Kannangara DRW, Graham GG, Wright DFB, et al. Individualising the dose of allopurinol in patients with gout. Br J Clin Pharmacol. 2017;83:2015\u201326.","journal-title":"Br J Clin Pharmacol"},{"key":"1559_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1172\/JCI107931","volume":"55","author":"EJ Weinman","year":"1975","unstructured":"Weinman EJ, Eknoyan G, Suki WN. The influence of the extracellular fluid volume on the tubular reabsorption of uric acid. J Clin Invest. 1975;55:283.","journal-title":"J Clin Invest"},{"key":"1559_CR16","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/annrheumdis-2011-201186","volume":"72","author":"MA McAdams-DeMarco","year":"2013","unstructured":"McAdams-DeMarco MA, Maynard JW, Baer AN, et al. A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC study. Ann Rheum Dis. 2013;72:701\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1559_CR17","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/rheumatology\/kew018","volume":"55","author":"S Mitnala","year":"2016","unstructured":"Mitnala S, Phipps-Green A, Franklin C, et al. Clinical and genetic features of diuretic-associated gout: a case-control study. Rheumatology (Oxford). 2016;55:1172\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"1559_CR18","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/ard.2005.040360","volume":"65","author":"HJEM Janssens","year":"2006","unstructured":"Janssens HJEM, van de Lisdonk EH, Janssen M, van den Hoogen HJM, Verbeek ALM. Gout, not induced by diuretics? A case-control study from primary care. Ann Rheum Dis. 2006;65:1080\u20133.","journal-title":"Ann Rheum Dis"},{"key":"1559_CR19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.semarthrit.2014.05.007","volume":"44","author":"LK Stamp","year":"2014","unstructured":"Stamp LK, Merriman TR, Barclay ML, et al. Impaired response or insufficient dosage? Examining the potential causes of \u201cinadequate response\u201d to allopurinol in the treatment of gout. Semin Arthritis Rheum. 2014;44:170\u20134.","journal-title":"Semin Arthritis Rheum"},{"key":"1559_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbrc.2014.08.068","volume":"452","author":"C Knake","year":"2014","unstructured":"Knake C, Stamp L, Bahn A. Molecular mechanism of an adverse drug-drug interaction of allopurinol and furosemide in gout treatment. Biochem Biophys Res Commun. 2014;452:157\u201362.","journal-title":"Biochem Biophys Res Commun"},{"key":"1559_CR21","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1093\/rheumatology\/kes091","volume":"51","author":"LK Stamp","year":"2012","unstructured":"Stamp LK, Barclay ML, O'Donnell JL, et al. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice. Rheumatology (Oxford). 2012;51:1670\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"1559_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/00000441-198610000-00006","volume":"292","author":"K Hande","year":"1986","unstructured":"Hande K, et al. Evaluation of a thiazide-allopurinol drug interaction. Am J Med Sci. 1986;292:213\u20136.","journal-title":"Am J Med Sci"},{"key":"1559_CR23","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/BF00577758","volume":"72","author":"W Loffler","year":"1994","unstructured":"Loffler W, Landthaler R, de Vries J, et al. Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. Clin Investig. 1994;72:1071\u20135.","journal-title":"Clin Investig"},{"key":"1559_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1365-2125.2010.03667.x","volume":"70","author":"B Grabowski","year":"2010","unstructured":"Grabowski B, Khosravan R, Wu JT, et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. Br J Clin Pharmacol. 2010;70:57\u201364.","journal-title":"Br J Clin Pharmacol"},{"key":"1559_CR25","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1002\/art.30649","volume":"63","author":"F Perez-Ruiz","year":"2011","unstructured":"Perez-Ruiz F, Herrero-Beites AM, Carmona L. A two-stage approach to the treatment of hyperuricemia in gout: the \u201cdirty dish\u201d hypothesis. Arthritis Rheum. 2011;63:4002\u20136.","journal-title":"Arthritis Rheum"},{"key":"1559_CR26","first-page":"2437","volume":"30","author":"J Darmawan","year":"2003","unstructured":"Darmawan J, Rasker JJ, Nuralim H. The effect of control and self-medication of chronic gout in a developing country. Outcome after 10 years. J Rheumatol. 2003;30:2437\u201343.","journal-title":"J Rheumatol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1559-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1559-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1559-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T20:34:22Z","timestamp":1553200462000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1559-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,22]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1559"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1559-2","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,22]]},"assertion":[{"value":"26 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethics committee of the Hospital General Universitario de Alicante (2017\/05 act) and the Spanish drugs regulatory administration approved this study; according to these organisations, informed consent was not necessary due to the retrospective nature of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MA has received speaking and advisory fees from Menarini, Astra-Zeneca, Horizon, and Gr\u00fcnenthal. The other authors declare no conflicts of interest in the conduct of the present study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"53"}}